AC Immune (ACIU) Invested Capital (2016 - 2025)
AC Immune (ACIU) has disclosed Invested Capital for 10 consecutive years, with $74.5 million as the latest value for Q4 2025.
- Quarterly Invested Capital fell 50.71% to $74.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $74.5 million through Dec 2025, down 50.71% year-over-year, with the annual reading at $74.5 million for FY2025, 50.71% down from the prior year.
- Invested Capital for Q4 2025 was $74.5 million at AC Immune, down from $151.2 million in the prior quarter.
- The five-year high for Invested Capital was $275.1 million in Q4 2021, with the low at $74.5 million in Q4 2025.
- Average Invested Capital over 5 years is $177.9 million, with a median of $189.1 million recorded in 2022.
- The sharpest move saw Invested Capital rose 7.66% in 2021, then crashed 50.71% in 2025.
- Over 5 years, Invested Capital stood at $275.1 million in 2021, then tumbled by 31.26% to $189.1 million in 2022, then increased by 5.49% to $199.4 million in 2023, then dropped by 24.19% to $151.2 million in 2024, then plummeted by 50.71% to $74.5 million in 2025.
- According to Business Quant data, Invested Capital over the past three periods came in at $74.5 million, $151.2 million, and $199.4 million for Q4 2025, Q4 2024, and Q4 2023 respectively.